Table 1.
Demographic and Clinical Characteristics of Severe Acute Respiratory Syndrome Coronavirus 2–Naive Patients at Baseline and Humoral and Cellular Response to BNT162b2 Vaccine at 4 and 8 Weeks
| Characteristic | All Patients (N = 189) |
Patients With Information on Frailty (n = 75) |
|---|---|---|
| Age | ||
| <75 y | 91 (48.1) | 26 (34.7) |
| 75–84 y | 74 (39.2) | 38 (50.7) |
| ≥85 y | 24 (12.7) | 11 (14.7) |
| Mean ± SD | 71.4 ± 14.6 | 75.1 ± 13.1 |
| Male sex | 131 (69.3) | 46 (61.3) |
| BMI, kg/m2, mean ± SD | 26.2 ± 5.1 | 26.5 ± 5.3 |
| Current smoker | 36 (19.0) | 8 (10.7) |
| Comorbid disease | ||
| Coronary artery disease | 83 (43.9) | 28 (37.3) |
| Heart failure | 42 (22.2) | 16 (21.3) |
| Cerebrovascular disease | 46 (24.3) | 19 (25.3) |
| Peripheral vascular disease | 43 (22.8) | 18 (24.0) |
| Abdominal vascular disease | 24 (12.7) | 13 (17.3) |
| COPD | 14 (7.4) | 7 (9.3) |
| Diabetes, type 1 or 2 | 68 (36.0) | 22 (29.3) |
| Liver disease | 4 (2.1) | 1 (1.3) |
| Immunodeficiency | 19 (10.1) | 4 (5.3) |
| Malignancy | 41 (21.7) | 17 (22.7) |
| Hepatitis B vaccine nonresponder | 22 (14.2) | 10 (15.9) |
| ESRD causes | ||
| Diabetes | 42 (22.2) | 14 (18.7) |
| Vascular disease | 59 (31.2) | 27 (36.0) |
| Glomerular disease | 29 (15.3) | 10 (13.3) |
| Tubulointerstitial disease | 15 (7.9) | 6 (8.0) |
| ADPKD or other genetic disease | 9 (4.8) | 3 (4.0) |
| Other | 35 (18.5) | 15 (20.0) |
| Dialysis vintage, ya | 2.1 (1.1–4.6) | 2.6 (1.3–5.6) |
| Hemodiafiltration | 176 (93.1) | 73 (97.3) |
| Online Kt/V, mean ± SD | 1.50 ± 0.40 | 1.47 ± 0.31 |
| Medication | ||
| ACEI/ARB | 55 (29.1) | 28 (37.3) |
| Immunosuppressive drugs | 28 (14.8) | 10 (13.3) |
| Humoral response to BNT162b2 vaccine, AU/mLa | ||
| 4 weeks | 627.8 (62.7–2753.0) | 278.4 (6.8–2385.0) |
| 8 weeks | 1890.0 (570.8–4538.4) | 1466.0 (230.7–4186.4) |
| Cellular response to BNT162b2 vaccine, IU/mLa | ||
| 4 weeks | 0.76 (0.11–2.75) | 0.54 (0.06–2.76) |
| 8 weeks | 0.12 (0.03–0.61) | 0.12 (0.02–0.67) |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: ACEI/ARB, angiotenin-converting enzyme inhibitor/angiotensin receptor blocker; ADPKD, autosomal dominant polycystic kidney disease; BMI, body mass index; COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease; standard deviation.
a
Median (25th–75th percentile).